首页> 美国卫生研究院文献>Neuro-Oncology >P01.142 Comparing Outcomes in Glioblastoma Multiforme patients undergoing Photodynamic Therapy with a Second-Generation Photosensitiser vs 5-Aminolevulinic Acid - A Single Site Retrospective Analysis
【2h】

P01.142 Comparing Outcomes in Glioblastoma Multiforme patients undergoing Photodynamic Therapy with a Second-Generation Photosensitiser vs 5-Aminolevulinic Acid - A Single Site Retrospective Analysis

机译:P01.142比较第二代光敏剂与5-氨基乙酰丙酸与第二代光敏剂进行光动力治疗的多形胶质母细胞瘤患者的结果-单点回顾性分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundLaser light in malignant brain tumours has been used in conjunction with photosensitizing drugs to both guide surgical resection (Photodynamic Diagnosis (PDD)) and to also enhance the extent of tumour destruction (Photodynamic Therapy (PDT)).Photosensitizing drugs given pre-operatively are taken up by rapidly dividing cells, resulting in fluorescence on exposure to low visible wavelength (blue) light (PDD) or generate cytotoxic singlet oxygen species upon exposure to high visible wavelength (red) light (PDT). PDT potentially offers benefit for patients with Glioblastoma Multiforme (GBM) where it’s highly invasive & heterogeneous nature makes complete resection impossible. As 5-ALA has European & US regulatory approval for PDD in GBM surgery, it is the most obvious candidate for PDT. A newer agent, Temoporfin, has demonstrated greater phototoxicity in animal models and enhances survival over matched pair (no PDT) controls in humans. This retrospective analysis aims to establish whether PDT with Temoporfin confers a greater degree of survival for GBM patients compared to using PDT with 5-ALA while undergoing a standard regime of care (surgical debulking, followed by Temozolomide with radiotherapy).
机译:背景恶性脑肿瘤中的激光已与光敏药物结合使用,既可指导手术切除(光动力诊断(PDD)),又可增强肿瘤破坏的程度(光动力疗法(PDT))。通过迅速分裂的细胞吸收,在暴露于低可见光(蓝)光(PDD)时产生荧光,或者在暴露于高可见光(红)光(PDT)时产生细胞毒性单线态氧。 PDT可能为多形性胶质母细胞瘤(GBM)的患者带来好处,因为它具有高度侵入性和异质性,因此无法完全切除。由于5-ALA已获欧美监管机构批准GBM手术中的PDD,因此它是最明显的PDT候选药物。新型药物替莫泊芬(Temoporfin)在动物模型中显示出更高的光毒性,并且比人类中的配对对(无PDT)对照具有更高的存活率。这项回顾性分析旨在确定与接受5-ALA的PDT并接受标准护理方案(外科大手术,继而接受替莫唑胺的放射治疗)相比,含Temoporfin的PDT是否能为GBM患者带来更高的存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号